YOLFTbeta
Vyome Holdings, Inc.

Vyome Holdings, Inc.

HIND · NASDAQ · Healthcare / Biotechnology

1.58USD-0.05 (-3.07%)

Price History

Full chart

Market Stats

Previous Close1.63
Open1.60
Day Range1.57 – 1.61
52-Week Range1.75 – 6.56
Volume3.00K
Market Cap14.46M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.67
Dividend Yield0.00%
50-Day Avg2.13
200-Day Avg2.49

About

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Venkateswarlu Nelabhotla M.B.A.
  • Employees9
  • HeadquartersHarvard Square, Cambridge, MA, United States, 02138, USA
  • Websitehttps://www.vyometx.com

Leadership

  • Mr. Venkateswarlu Nelabhotla M.B.A.Co-Founder, CEO, President & Director · b. 1962
  • Dr. Shiladitya Sengupta M.Sc., Ph.D.Co-Founder, Director and Member of Scientific & Clinical Advisory Board · b. 1973
  • Mr. Jerry Leonard C.P.A., M.B.A.CFO, Principal Financial & Accounting Officer · b. 1968
  • Dr. Richard Fahrner Ph.D.Chief Technology Officer
  • Mr. Jules AbrahamInvestor Relations Officer
  • Dr. Charles G. Chavdarian Ph.D.Senior Vice President of Product Development & Regulatory CMC
  • Dr. Tamara Agajanov M.D.Senior Vice President of Clinical Development

Financials

Income Statement

Currency: USD2003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---------312.00K--292.00K786.66K1.29M606.71K15.09M11.30M13.60M11.24M8.68M8.01M319.71K
Growth (%)-------------+169.40%+63.62%-52.86%+2387.02%-25.12%+20.36%-17.35%-22.79%-7.74%-96.01%
Cost of Revenue---------232.00K--125.00K431.48K936.39K164.30K5.78M5.04M5.25M4.44M3.13M2.95M112.93K
Gross Profit---------80.00K--167.00K355.18K350.77K442.41K9.30M6.26M8.35M6.80M5.55M5.06M206.79K
Gross Margin---------25.64%--57.19%45.15%27.25%72.92%61.67%55.42%61.38%60.52%63.93%63.17%64.68%
Operating Expense---------22.63M--28.03M23.15M31.76M38.99M33.77M18.72M66.23M33.88M20.19M12.79M2.95M
Operating Income-1.90M-3.45M-11.15M-18.12M-28.03M-36.27M-24.21M-16.18M-25.26M-22.55M-24.73M-25.59M-27.87M-22.80M-31.41M-38.55M-24.46M-12.46M-57.88M-27.08M-14.64M-7.73M-2.75M
Operating Margin----------7227.24%---9543.49%-2897.77%-2440.10%-6353.28%-162.11%-110.25%-425.60%-240.91%-168.69%-96.53%-859.22%
EBITDA-1.90M-3.45M-11.02M-18.03M-26.58M-35.74M-16.50M-15.01M-24.92M-22.32M-24.56M-25.40M-27.68M-19.50M-34.39M-36.97M-72.94M-18.09M-60.62M-44.33M-11.18M-6.65M-10.32M
EBITDA Margin----------7154.48%---9478.53%-2479.47%-2671.86%-6092.70%-483.42%-160.15%-445.71%-394.38%-128.84%-83.01%-3227.60%
Net Income-1.90M-3.45M-11.22M-17.69M-28.58M-37.87M-31.93M-17.35M-26.00M-23.46M-25.78M-26.13M-25.50M-23.36M-33.82M-81.15M-74.21M-21.63M-63.15M-46.21M-11.39M-7.13M-10.26M
Net Income Margin----------7519.23%---8732.53%-2969.62%-2627.34%-13375.68%-491.80%-191.43%-464.31%-411.16%-131.22%-89.06%-3209.75%
R&D--8.83M14.36M21.05M27.67M15.58M8.50M16.67M10.67M11.07M11.03M8.14M5.17M5.78M5.72M3.12M3.50M2.37M2.54M2.31M1.80M588.26K
R&D as % of Total Revenue---------3419.23%--2788.36%657.12%448.67%943.14%20.68%30.96%17.42%22.57%26.68%22.52%184.00%
Interest Expense--181.15K710.11K1.65M2.68M4.10M1.26M722.86K901.84K932.36K530.22K939.18K4.10M3.87K12.00K451.00K2.05M832.00K113.00K164.68K206.00K146.64K
Interest Expense % of Total Revenue---------289.05%--321.64%521.70%0.30%1.98%2.99%18.13%6.12%1.01%1.90%2.57%45.87%

Balance Sheet

Currency: USD2003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets717.00K-11.56M36.06M59.05M28.28M16.21M38.69M32.49M26.10M26.39M14.39M11.59M7.04M88.70M46.27M39.66M39.71M52.53M11.27M10.73M4.79M6.50M
Total Liabilities1.39M-9.59M7.49M13.77M16.87M10.63M8.98M12.44M14.22M11.71M7.72M7.91M4.10M12.34M14.61M15.55M25.23M8.20M7.60M4.06M5.05M2.74M
Total Equity-670.00K-1.97M28.57M45.28M11.41M5.58M29.71M20.04M11.88M14.68M6.66M3.67M2.94M76.37M31.66M24.11M14.49M44.33M3.66M6.66M-253.00K2.44M
Cash--10.72M17.54M48.73M21.06M14.62M30.84M28.49M22.31M23.30M11.62M7.93M3.31M10.16M5.55M2.94M3.01M22.77M3.96M4.56M693.00K4.98M
Total Debt--8.34M4.38M11.10M13.67M7.76M5.91M5.19M9.68M6.87M2.98M1.27M143.69K488.61K6.31M5.41M13.25M279.00K171.00K262.00K967.00K31.26K
Net Debt---2.38M-13.16M-37.63M-7.38M-6.86M-24.94M-23.30M-12.63M-16.43M-8.64M-6.66M-3.17M-9.67M762.47K2.47M10.25M-22.49M-3.78M-4.30M274.00K-4.95M

Cash Flow

Currency: USD2005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-10.28M-16.23M-23.37M-33.67M-24.66M-13.66M-19.94M-22.48M-18.43M-19.38M-22.61M-20.66M-24.59M-27.49M-14.20M-8.55M-15.38M-21.90M-16.96M-4.43M-3.75M
Investing Cash Flow-449.81K-17.67M8.25M2.83M5.04M-6.53M5.07M923.61K-216.01K-88.68K-38.91K-14.00K-6.37M-10.33M-2.01M-2.39M1.85M-92.00K-10.00K--
Financing Cash Flow16.11M40.72M46.32M3.16M13.18M36.42M12.52M15.38M19.63M7.79M18.95M16.05M37.81M33.20M13.66M11.07M33.30M3.13M17.57M677.00K8.65M
Capital Expenditure449.81K634.97K800.39K244.44K186.98K2.59K252.27K76.39K416.01K88.68K38.91K14.00K137.12K49.58K14.00K390.00K352.00K131.00K43.00K03
Free Cash Flow-10.73M-16.86M-24.17M-33.91M-24.84M-13.67M-20.19M-22.56M-18.84M-19.47M-22.64M-20.67M-24.73M-27.54M-14.21M-8.94M-15.73M-22.03M-17.00M-4.43M-3.75M
FCF to OCF104.38%103.91%103.43%100.73%100.76%100.02%101.27%100.34%102.26%100.46%100.17%100.07%100.56%100.18%100.10%104.56%102.29%100.60%100.25%100.00%100.00%

Earnings

Report DateNov 11, 2016Feb 23, 2017May 10, 2017Aug 2, 2017Nov 3, 2017Mar 6, 2018May 11, 2018Aug 2, 2018Nov 2, 2018Feb 22, 2019May 10, 2019Jul 24, 2019Nov 8, 2019Feb 27, 2020Jun 19, 2020Jul 30, 2020Nov 6, 2020Mar 12, 2021May 12, 2021Aug 16, 2021Nov 11, 2021Mar 28, 2022May 23, 2022Aug 15, 2022Nov 14, 2022May 15, 2023Aug 8, 2023Nov 9, 2023May 16, 2024Aug 15, 2024Nov 15, 2024Apr 4, 2025Aug 14, 2025Nov 14, 2025Mar 30, 2026May 26, 2026Aug 12, 2026Nov 13, 2026
EPS Estimate---------------25.50-15.00-3.50-3.00--0.22-0.15-0.17-0.34-0.51-32.50-10.00------0.07--0.11-0.34-0.18-0.19-
EPS Actual-1000000.00-1000000.00-1000000.00-1000000.00-1000000.00-1000000.00-1000000.00-1000000.00-1000000.00-1000000.00-1000000.00-1000000.00-531940.09-555633.92-2.04-1.63-0.61-0.51-1.32-0.15-0.31-1.73-0.38-0.51-0.58-34.02-6235.08-5936.62-542.24-366.78-310.70-2.47-9.00-3.12-0.21-0.14-0.10-
Surprise--------------92.00%89.13%82.57%83.00%-33.55%-104.07%-888.57%-10.64%0.98%98.20%-240.20%------3428.57%--2736.36%39.12%20.06%47.37%-
Timing---------------------------------After-hours--After-hours-

Key Statistics & Ratios

Market Cap14.46M
Enterprise Value6.10M
Trailing P/E0.00
Forward P/E0.00
Price / Sales111.45
Price / Book2.31
EPS-1.67
Book Value0.862
Revenue (TTM)129.72K
Gross Profit (TTM)68.42K
EBITDA-4.21M
Profit Margin0.00%
Operating Margin-3200.02%
Return on Equity-999.17%
Return on Assets-48.79%
Shares Outstanding7.02M
Shares Float3.65M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
2.18%
Insiders
52.88%
Retail / Other
44.94%

Top Institutional Holders

  • Citadel Advisors Llc
    25.97K0.37%
  • Geode Capital Management, LLC
    25.79K0.37%
  • UBS Group AG
    22.68K0.32%
  • The Colony Group LLC
    14.64K0.21%
  • Vanguard Fiduciary Trust Co
    12.20K0.17%
  • Vanguard Capital Management, LLC
    9.46K0.13%
  • Royal Bank of Canada
    5.86K0.08%
  • Tower Research Capital LLC
    1.39K0.02%
  • Citigroup Inc
    160.00%
  • Caitong International Asset Management Co., Limited.
    20.00%
  • Millennium Management LLC
    00.00%
  • Bank of America Corp
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    16.29K0.23%
  • Fintech Income SICAV
    5.80K0.08%
  • Cinvest Multigestión Garp FI
    5.80K0.08%
  • Fidelity Series Total Market Index
    3.21K0.05%

Stock Splits

  • Aug 15, 20251:4
  • May 9, 20251:25
  • Sep 23, 20241:58
  • Dec 23, 20221:50
  • Jul 25, 20191:10